Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Im Cannabis Corp (IMCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IMCC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.22
1 Year Target Price $8.22
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.95% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.21M USD | Price to earnings Ratio - | 1Y Target Price 8.22 |
Price to earnings Ratio - | 1Y Target Price 8.22 | ||
Volume (30-day avg) 1 | Beta 2.07 | 52 Weeks Range 1.29 - 7.12 | Updated Date 08/15/2025 |
52 Weeks Range 1.29 - 7.12 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-08-12 | When - | Estimate - | Actual -0.0685 |
Profitability
Profit Margin -3.75% | Operating Margin (TTM) -2.76% |
Management Effectiveness
Return on Assets (TTM) -2.96% | Return on Equity (TTM) -48.5% |
Valuation
Trailing PE - | Forward PE 16.31 | Enterprise Value 26448381 | Price to Sales(TTM) 0.31 |
Enterprise Value 26448381 | Price to Sales(TTM) 0.31 | ||
Enterprise Value to Revenue 0.7 | Enterprise Value to EBITDA 9.21 | Shares Outstanding 6094810 | Shares Floating 2114761 |
Shares Outstanding 6094810 | Shares Floating 2114761 | ||
Percent Insiders 45.63 | Percent Institutions 4.16 |
Upturn AI SWOT
Im Cannabis Corp
Company Overview
History and Background
Im Cannabis Corp focuses on medical cannabis in Israel and recreational cannabis in Canada. It was founded to address unmet medical needs with high-quality cannabis products.
Core Business Areas
- Medical Cannabis (Israel): Cultivation, processing, and distribution of medical-grade cannabis products to patients in Israel.
- Recreational Cannabis (Canada): Production, distribution, and sale of recreational cannabis products in the Canadian market.
Leadership and Structure
Information unavailable, as no public US company with this name has been identified. Therefore, leadership and structural details cannot be accurately provided.
Top Products and Market Share
Key Offerings
- Medical Cannabis Products: Variety of cannabis strains, oils, and topical products for medical use in Israel. Market share data not readily available. Competitors include Canndoc and Panaxia Pharmaceutical Industries.
- Recreational Cannabis Products: Dried flower, pre-rolls, edibles, and vape products sold in Canada. Market share data not readily available. Competitors include Canopy Growth and Aurora Cannabis.
Market Dynamics
Industry Overview
The cannabis industry is experiencing rapid growth and regulatory changes, driven by increasing legalization globally. The industry is becoming increasingly competitive.
Positioning
Positioning is difficult to determine without specific information on Im Cannabis Corp. Assumed focus on premium medical cannabis and recreational markets.
Total Addressable Market (TAM)
Cannabis industry TAM is estimated to reach hundreds of billions of dollars globally within the next decade. Im Cannabis Corp's positioning within this TAM depends on market share and product portfolio performance.
Upturn SWOT Analysis
Strengths
- Strong Presence in Israeli Medical Cannabis Market
- Product Innovation Capabilities
- Established Distribution Networks
Weaknesses
- Limited Geographic Diversification
- Dependence on Regulatory Environment
- Financial Constraints
Opportunities
- Expansion into New Geographic Markets
- Development of New Cannabis Products
- Strategic Partnerships and Acquisitions
Threats
- Increased Competition
- Changing Regulations
- Price Volatility
Competitors and Market Share
Key Competitors
- CGC
- ACB
- TLRY
Competitive Landscape
Without specific information, it is difficult to accurately assess the competitive landscape for Im Cannabis Corp. The market is highly competitive.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not available for a public US company with this name.
Future Projections: Future Projections data is not available for a public US company with this name.
Recent Initiatives: Recent Initiatives data is not available for a public US company with this name.
Summary
Based on the limited information, it's challenging to evaluate Im Cannabis Corp's financial strength. A strong presence in medical cannabis is positive. Dependence on specific markets and regulation may pose risks. Expansion and product innovation are essential for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available industry reports and market analyses.
Disclaimers:
This analysis is based on limited information and assumptions. Market share data is estimated. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Im Cannabis Corp
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-05-20 | Executive Chairman & CEO Mr. Oren Shuster | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://imcannabis.com |
Full time employees - | Website https://imcannabis.com | ||
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.